Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠High Leverage ⢠Thin Cash Flow PAHC offers strong profitability and liquidity at a moderate valuation, but high leverage and weak free-cash-flow conversion warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Multiweek gain intact ⢠Near-term reversal ⢠Support test Support Level: $35.00â$35.20 Resistance Level: $37.50â$38.25 PAHC retains a bullish last-month gain but near-term momentum is weak below $36.36; hold $35.00â$35.20 support or reclaim $37.50â$38.25 for a stronger outlook.
Sentiment & News
Key News Insights: ⢠Earnings Outperformance ⢠Zoetis Integration ⢠Price Weakness Phibro's earnings beat, record sales, and Zoetis integration support improving fundamentals, though weak share-price momentum keeps guidance and upcoming investor events in focus.
AI Summary
PAHC's Zoetis acquisition has validated earnings growth, but the investment case now hinges on converting EBITDA into free cash flow through inventory normalization and deleveraging; investors should remain cautious until cash conversion improves, particularly given Brazil regulatory risk and ~2.8x net leverage.
Description
Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum. | Closed | -7.8% |
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile. | Closed | +12.8% |